Table 2. Relationship between the... | American Society of Hematology

Table 2.

Relationship between the doubling time of WT1and the efficacy of immunomodulation therapy in patients with relapse

No.	UPN	Disease	State at transplantation	Doubling time, d	Efficacy
No.	UPN	Disease	State at transplantation	Doubling time, d	DLI	Reduction in IS
1	242	AML	Non-CR	2.7	ND	−
2	242^*	AML	Non-CR	2.9	ND	−
3	184	AML	Non-CR	4.8	ND	−
4	264	AML	CR1	5.0	ND	−
5	201	AML	Non-CR	5.8	−	−
6	201^*	AML	Non-CR	5.8	ND	−
7	206	ALL	Non-CR	7.0	ND	−
8	70	AML	CR1	10	−	−
9	238	AML	Non-CR	13	ND	−
10	189	AML	Non-CR	13	ND	+
11	197	AML	Non-CR	13	ND	+
12	77	AML	CR1	26	ND	+
13	163^†	AML	CR1	28	+	+
14	31	AML	CR1	47	−	−
15	58	AML	CR1	130	+	ND

No.	UPN	Disease	State at transplantation	Doubling time, d	Efficacy
No.	UPN	Disease	State at transplantation	Doubling time, d	DLI	Reduction in IS
1	242	AML	Non-CR	2.7	ND	−
2	242^*	AML	Non-CR	2.9	ND	−
3	184	AML	Non-CR	4.8	ND	−
4	264	AML	CR1	5.0	ND	−
5	201	AML	Non-CR	5.8	−	−
6	201^*	AML	Non-CR	5.8	ND	−
7	206	ALL	Non-CR	7.0	ND	−
8	70	AML	CR1	10	−	−
9	238	AML	Non-CR	13	ND	−
10	189	AML	Non-CR	13	ND	+
11	197	AML	Non-CR	13	ND	+
12	77	AML	CR1	26	ND	+
13	163^†	AML	CR1	28	+	+
14	31	AML	CR1	47	−	−
15	58	AML	CR1	130	+	ND

UPN indicates unique patient number; IS, a rapid reduction of immunosuppressants; HR, hematologic relapse; ND, not determined; +, effective; and −, not effective.

Second transplantation.

†

The patient (UPN 163) underwent DLI with the discontinuation of IS.

View Large

This Feature Is Available To Subscribers Only